Patients’ characteristics
| Characteristic . | . |
|---|---|
| Age median, (range) | 71 (62-84) |
| Male/female | 37/13 (73/27) |
| MIPI risk group, n (%) | |
| Low | 5 (10) |
| Intermediate | 19 (38) |
| High | 26 (52) |
| Extra nodal sites (n) | |
| 0 | 9 |
| 1 | 24 |
| 2 | 10 |
| 3 | 3 |
| 4 | 3 |
| Missing data | 2 |
| Prior treatment (1 cycle), n (%) | 4 (8) |
| 1 R-CHOP | 2 (4) |
| 1 R-Bendamustine | 1 (2) |
| 1 R-ARA-C | 1 (2) |
| WHO performance status, n (%) | |
| 0 | 25 (50) |
| 1 | 22 (44) |
| 2 | 3 (6) |
| Ann Arbor stage, n (%) | |
| II | 2 (4) |
| III | 4 (8) |
| IV | 44 (88) |
| Median leukocyte count, (n × 10 9/mm3) | 8.4 (1.7-135.9) |
| Characteristic . | . |
|---|---|
| Age median, (range) | 71 (62-84) |
| Male/female | 37/13 (73/27) |
| MIPI risk group, n (%) | |
| Low | 5 (10) |
| Intermediate | 19 (38) |
| High | 26 (52) |
| Extra nodal sites (n) | |
| 0 | 9 |
| 1 | 24 |
| 2 | 10 |
| 3 | 3 |
| 4 | 3 |
| Missing data | 2 |
| Prior treatment (1 cycle), n (%) | 4 (8) |
| 1 R-CHOP | 2 (4) |
| 1 R-Bendamustine | 1 (2) |
| 1 R-ARA-C | 1 (2) |
| WHO performance status, n (%) | |
| 0 | 25 (50) |
| 1 | 22 (44) |
| 2 | 3 (6) |
| Ann Arbor stage, n (%) | |
| II | 2 (4) |
| III | 4 (8) |
| IV | 44 (88) |
| Median leukocyte count, (n × 10 9/mm3) | 8.4 (1.7-135.9) |
MIPI, Mantle Cell Lymphoma International Prognostic Index.